Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Operating Expenses (2018 - 2025)

Historic Other Operating Expenses for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Q3 2025 value amounting to $5000.0.

  • Lineage Cell Therapeutics' Other Operating Expenses fell 8684.21% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 827444.44%. This contributed to the annual value of $334000.0 for FY2024, which is 5022.35% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Other Operating Expenses is $5000.0, which was down 8684.21% from $14.9 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Other Operating Expenses high stood at $14.9 million for Q2 2025, and its period low was $5000.0 during Q3 2025.
  • Moreover, its 3-year median value for Other Operating Expenses was $108500.0 (2023), whereas its average is $1.6 million.
  • Over the last 5 years, Lineage Cell Therapeutics' Other Operating Expenses had its largest YoY gain of 3371590.91% in 2025, and its largest YoY loss of 8684.21% in 2025.
  • Lineage Cell Therapeutics' Other Operating Expenses (Quarter) stood at $169000.0 in 2023, then decreased by 8.88% to $154000.0 in 2024, then tumbled by 96.75% to $5000.0 in 2025.
  • Its Other Operating Expenses was $5000.0 in Q3 2025, compared to $14.9 million in Q2 2025 and $36000.0 in Q1 2025.